+29%

est. 2Y upside i

HealthcareSeries A

Rank

#1389

Sector

Biotechnology

Est. Liquidity

~5Y

Data Quality

Data: Low

Equity upside is highly speculative due to missing financial data.

Last updated: July 3, 2026

Bull (10%)+380%

FDA Modernization Act accelerates adoption; Vivodyne becomes dominant platform for preclinical testing. Exit via acquisition at $1B+ valuation within 5 years.

Base (45%)+80%

Steady commercial traction with pharma partnerships; revenue grows to ~$50M by 2028. Exit valuation at $360M (1.8x entry) before dilution.

Bear (45%)-100%

Failure to secure FDA acceptance of non-animal data; competition from Emulate/CN Bio erodes market share. Common stock worthless.

Est. time to liquidity~5.0 years

Preference Stack Risk

severe

Funding Intensity

5900%

Total funding $118M equals 59% of estimated $200M entry valuation, giving preferred a large liquidation preference over common stock.

Dilution Risk

high

Series A closed May 2025 with $40M; with high burn rate, another round within 24 months is likely, causing significant dilution for existing common holders.

Secondary Liquidity

none

No secondary market indicated; shares are illiquid until a liquidity event (IPO or acquisition).

Other — 4 roles

View all 4 open roles at Vivodyne →

Last updated: February 22, 2026

Questions to Ask at the Interview

Strategic questions based on Vivodyne's data — designed to show you've done your homework.

  • 1

    “How does Vivodyne's data compare to traditional animal studies in terms of regulatory acceptance? (strategic)”

  • 2

    “What is the unit economics of a typical DaaS partnership, and how do gross margins scale with utilization? (business model)”

  • 3

    “Given the heavy preference stack and likely future raises, how much dilution do you expect for common holders, and what liquidity path does the company anticipate? (equity/career)”

Community

Valuation Sentiment

Our model estimates +29% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.